Preparation and In Vitro and In Vivo Evaluation of a Testosterone Film Forming Gel for the Treatment of Hypoactive Sexual Desire Disorder in Women

被引:3
|
作者
Zeng, Jia [1 ]
Xie, Tan-Fang [2 ]
Huang, Ting [1 ]
Li, Fang [1 ]
Wang, Zhi-Ping [2 ]
Feng, Ling-Lin [1 ]
机构
[1] Shanghai Engineer & Technol Res Ctr Reprod Hlth D, Shanghai Inst Biomed & Pharmaceut Technol, NHC Key Lab Reprod Regulat, Shanghai 200032, Peoples R China
[2] Guangxi Univ Chinese Med, Dept Pharmaceut, Key Lab Common Technol Tradit Chinese Med Prepara, Nanning 530020, Peoples R China
关键词
testosterone; film forming gel; Transcutol P; in vitro; in vivo; SURGICALLY MENOPAUSAL WOMEN; POSTMENOPAUSAL WOMEN; SKIN PERMEATION; UNITED-STATES; DELIVERY; REAPPRAISAL; FORMULATION; PREVALENCE; TRANSCUTOL; MOTIVATION;
D O I
10.1208/s12249-021-02201-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hypoactive sexual desire disorder (HSDD) is one of the most common sexual complaints in women. Currently, there is an unmet need for a drug treatment for this disorder. The purpose of this study was to develop a testosterone (TS) film forming gel used for women to treat HSDD by measuring the tackiness, peel adhesion force, tensile strength, and elasticity of the formulation. Diethylene glycol monoethyl ether (Transcutol P), an efficient penetration enhancer, was added to the optimized formulation and the transdermal permeation characteristics in vitro were studied using Franz-diffusion cells. The quantitative determination of TS was performed by high-performance liquid chromatography (HPLC). After 24 h, Transcutol P at 3% had the largest cumulative amount of drug and enhancement ratio of TS of 75.14 mu g/cm(2) and 2.82, respectively. After the screening of film forming polymers and penetration enhancers, the optimal formulation was as follows: glycerol (1%, w/w); 12.5% sodium carboxymethylcellulose (CMC-Na) aqueous solution (0.5%, w/w); 2.5% Carbomer ethanol solution (0.5%, w/w); Transcutol P ethanol solution (3%, w/w) containing 0.5% TS; and 8% Poly vinyl alcohol (PVA) aqueous solution (30%, w/w). The optimized film forming gel had good uniformity and the release of TS in vitro was close to 100% within 24 h. In vivo studies showed the formulations had optimal area under blood drug concentration curve values in the order of 3% Transcutol P > 1% Transcutol P > 5% Transcutol P > control preparation. The formulation with 3% Transcutol P provided the highest permeation effect both in vitro and in vivo. The safety of this formulation was further evaluated with a skin irritation test. It could effectively improve the rabbit skin irritation observed with a marketed transdermal patch Androderm (R). The present study provides a promising approach for the development of a novel TS film forming gel for the treatment of HSDD in women.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Hypoactive Sexual Desire Disorder in Postmenopausal Women: Quality of Life and Health Burden
    Biddle, Andrea K.
    West, Suzanne L.
    D'Aloisio, Aimee A.
    Wheeler, Stephanie B.
    Borisov, Natalie N.
    Thorp, John
    VALUE IN HEALTH, 2009, 12 (05) : 763 - 772
  • [32] Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women
    Barakeh, Donna
    Mdaihly, Hadil
    Karaoui, Lamis R.
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (02) : 148 - 161
  • [33] Incidence and Predictors of Low Sexual Desire and Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-Analysis
    Tetik, Sinan
    Alkar, Ozden Yalcinkaya
    JOURNAL OF SEX & MARITAL THERAPY, 2023, 49 (07) : 842 - 865
  • [34] The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review
    Uloko, Maria
    Rahman, Farah
    Puri, Leah Ibrahim
    Rubin, Rachel S.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2022, 34 (07) : 635 - 641
  • [35] The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: A report of gender differences
    Bloch, Miki
    Meiboom, Hadas
    Zaig, Inbar
    Schreiber, Shaul
    Abramov, Liora
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (08) : 910 - 918
  • [36] Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study
    Kronawitter, Desiree
    Gooren, Louis J.
    Zollver, Hendryk
    Oppelt, Patricia G.
    Beckmann, Matthias W.
    Dittrich, Ralf
    Mueller, Andreas
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (02) : 363 - 368
  • [37] Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians
    Cocchetti, Carlotta
    Ristori, Jiska
    Mazzoli, Francesca
    Vignozzi, Linda
    Maggi, Mario
    Fisher, Alessandra Daphne
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2021, 33 (07) : 703 - 709
  • [38] Sexual Arousal and Lubrication Problems in Women With Clinically Diagnosed Hypoactive Sexual Desire Disorder: Preliminary Findings from the Hypoactive Sexual Desire Disorder Registry for Women
    Maserejian, Nancy N.
    Shifren, Jan
    Parish, Sharon J.
    Segraves, R. Taylor
    Huang, Liyuan
    Rosen, Raymond C.
    JOURNAL OF SEX & MARITAL THERAPY, 2012, 38 (01) : 41 - 62
  • [39] Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder
    Revicki, Dennis A.
    Althof, Stanley E.
    Derogatis, Leonard R.
    Kingsberg, Sheryl A.
    Wilson, Hilary
    Sadiq, Amama
    Krop, Julie
    Jordan, Robert
    Lucas, Johna
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2020, 4 (01)
  • [40] International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
    Parish, Sharon J.
    Simon, James A.
    Davis, Susan R.
    Giraldi, Annamaria
    Goldstein, Irwin
    Goldstein, Sue W.
    Kim, Noel N.
    Kingsberg, Sheryl A.
    Morgentaler, Abraham
    Nappi, Rossella E.
    Park, Kwangsung
    Stuenkel, Cynthia A.
    Traish, Abdulmaged M.
    Vignozzi, Linda
    JOURNAL OF SEXUAL MEDICINE, 2021, 18 (05) : 849 - 867